Eiger Biopharmaceuticals Inc

General ticker "EIGR" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $9.5M

Eiger Biopharmaceuticals Inc does not follow the US Stock Market performance with the rate: -29.4%.

Estimated limits based on current volatility of 6.2%: low 2.27$, high 2.57$

Factors to consider:

  • Earnings for 12 months up through Q4 are below our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term predictions were made for the period from 2022-12-31 to 2024-12-30

  • 2022-12-31 to 2023-12-31 predicted range: [28.46$, 92.94$]
  • 2023-12-31 to 2024-12-30 predicted range: [22.53$, 66.00$]

Financial Metrics affecting the EIGR estimates:

  • Negative: Non-GAAP EPS of -70.27 <= 0.09
  • Negative: Operating Income to Revenue ratio of -0.87 <= 0.01
  • Negative: Operating Cash Flow per share of -59.82 <= 0.22
  • Negative: negative Net Income
  • Negative: Industry Operating Cash Flow per share (median) of -1.67 <= 0.29
  • Negative: Interest Expense per share of 2.98 > 0.84
  • Negative: Industry Earnings per Price (median) of -0.26 <= 0

Similar symbols

Short-term EIGR quotes

Long-term EIGR plot with estimates

Financial data

YTD 2020-12-31 2021-12-31 2022-12-31
Operating Revenue $0.00MM $12.14MM $13.48MM
Operating Expenses $62.15MM $89.08MM $106.22MM
Operating Income $-62.15MM $-76.94MM $-92.74MM
Non-Operating Income $-2.90MM $43.09MM $-4.01MM
Interest Expense $3.59MM $3.56MM $4.13MM
R&D Expense $41.59MM $64.44MM $75.28MM
Income(Loss) $-65.05MM $-33.85MM $-96.75MM
Taxes $0.00MM $0.06MM $0.02MM
Profit(Loss) $-65.05MM $-33.92MM $-96.78MM
Stockholders Equity $95.03MM $72.40MM $55.31MM
Assets $143.59MM $126.40MM $120.14MM
Operating Cash Flow $-63.19MM $-71.34MM $-83.01MM
Investing Cash Flow $-44.79MM $61.53MM $9.63MM
Financing Cash Flow $97.46MM $3.17MM $76.95MM
Earnings Per Share* $-2.30 $-0.98 $-69.74

* EPS are Split Adjusted, recent splits may be reflected with a delay.